J. McDonald

发表

Phosphorylation of the Gq/11-coupled M3-Muscarinic Receptor Is Involved in Receptor Activation of the ERK-1/2 Mitogen-activated Protein Kinase Pathway*

A. Tobin, D. Budd, G. Willars, 2001, The Journal of Biological Chemistry.

Urotensin-II peptidomimetic incorporating a non-reducible 1,5-triazole disulfide bond reveals a pseudo-irreversible covalent binding mechanism to the urotensin G-protein coupled receptor.

D. Lambert, Rachel E. Foreman, R. Guerrini, 2017, Organic & biomolecular chemistry.

Structure–activity relationship study on Tyr9 of urotensin-II(4–11): Identification of a partial agonist of the UT receptor

S. Salvadori, D. Lambert, G. Calo’, 2009, Peptides.

Role of urotensin II and its receptor in health and disease

D. Lambert, J. McDonald, M. Batuwangala, 2007, Journal of Anesthesia.

Abstracts of the Spring Anaesthetic Research Society Meeting (ARS) The Royal College of Anaesthetists, London, UK, April 21–22, 2015

P. J. Devereaux, B. McGrath, R. Pearse, 2015 .

Binding of GTPγ[35S] is regulated by GDP and receptor activation. Studies with the nociceptin/orphanin FQ receptor

D. Lambert, J. McDonald, 2010, British journal of pharmacology.

Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Cα,α-dialkylated amino acids

S. Salvadori, D. Lambert, G. Calo’, 2007 .

Functional consequences of nociceptin receptor activation

J. McDonald, 2007 .

Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1–14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1–14)NH2

D. Lambert, G. Calo’, R. Guerrini, 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

Hot topics in opioid pharmacology: mixed and biased opioids.

D. Lambert, J. McDonald, Ammar A H Azzam, 2019, British journal of anaesthesia.

In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP‐505

S. Salvadori, C. Ghelardini, D. Lambert, 2018, British journal of pharmacology.

Drug–receptor interactions in anaesthesia

J. McDonald, D. G. Lambert, 2021, BJA Education.

Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24.

S. Salvadori, D. Lambert, G. Calo’, 2009, European journal of pharmacology.

Properdin Levels in Human Sepsis

D. Lambert, J. McDonald, Jonathan P Thompson, 2015, Front. Immunol..

Phosphorylation and Activity of Na+/H+ Exchanger Isoform 1 of Immortalized Lymphoblasts in Diabetic Nephropathy

B. Krolewski, A. Krolewski, J. McDonald, 1995, Diabetes.

The C-terminal Tail of the M3-muscarinic Receptor Possesses Anti-apoptotic Properties*

A. Tobin, D. Budd, K. Cain, 2003, Journal of Biological Chemistry.

Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505).

D. Lambert, G. Calo’, R. Guerrini, 2012, British journal of anaesthesia.

Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.

V. Hruby, S. Salvadori, D. Lambert, 2015, British journal of anaesthesia.

Urotensin II receptor expression in human right atrium and aorta: effects of ischaemic heart disease.

S. P. Young, D. Lambert, J. McDonald, 2009, British journal of anaesthesia.

Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity

D. Lambert, G. Calo’, R. Guerrini, 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma

C. Brightling, A. De Angelis, K. Urbanek, 2016, British journal of pharmacology.

Characterization of anandamide-stimulated cannabinoid receptor signaling in human ULTR myometrial smooth muscle cells.

D. Lambert, A. Taylor, J. McDonald, 2009, Molecular endocrinology.

Effects of receptor density on Nociceptin/OrphaninFQ peptide receptor desensitisation: studies using the ecdysone inducible expression system

D. Lambert, D. Rowbotham, J. McDonald, 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

Synthesis, Biological Activity and Molecular Docking of Chimeric Peptides Targeting Opioid and NOP Receptors

L. Gentilucci, A. Janecka, D. Lambert, 2022, International journal of molecular sciences.

Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.

S. Salvadori, D. Lambert, G. Calo’, 2009, Bioorganic & medicinal chemistry.

Human Peripheral Blood Mononuclear Cells Express Nociceptin/Orphanin FQ, but Not &mgr;, &dgr;, or &kgr; Opioid Receptors

D. Lambert, D. Rowbotham, J. McDonald, 2007, Anesthesia and analgesia.

In vitro pharmacological characterisation of a novel cyclic nociceptin/orphanin FQ analogue c[Cys7,10]N/OFQ(1–13)NH2

D. Lambert, G. Calo’, R. Guerrini, 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In Vitro Studies

D. Lambert, M. Morari, G. Calo’, 2007, Journal of Pharmacology and Experimental Therapeutics.

Assessment of the activity of a novel nociceptin/orphanin FQ analogue at recombinant human nociceptin/orphanin FQ receptors expressed in Chinese hamster ovary cells

D. Lambert, G. Calo’, R. Guerrini, 2003, Neuroscience Letters.

UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPγ35S binding studies

D. Lambert, G. Calo’, R. Guerrini, 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[Dmt1]N/OFQ(1–13)‐NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist

S. Salvadori, D. Lambert, P. Molinari, 2012, British journal of pharmacology.

Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha,alpha-dialkylated amino acids.

S. Salvadori, D. Lambert, G. Calo’, 2007, Bioorganic & medicinal chemistry.

Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1-13)NH(2) on GTPgamma(35)S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor.

D. Lambert, G. Calo’, R. Guerrini, 2002, European journal of pharmacology.

Opioid mechanisms and opioid drugs

D. Lambert, J. McDonald, 2008 .

In vitro sepsis induces Nociceptin/Orphanin FQ receptor (NOP) expression in primary human vascular endothelial but not smooth muscle cells

D. Lambert, G. Calo’, R. Guerrini, 2022, PloS one.

Assessment of nociceptin/orphanin FQ and micro-opioid receptor mRNA in the human right atrium.

S. P. Young, D. Lambert, J. McDonald, 2010, British journal of anaesthesia.

MOP and NOP receptor interaction: Studies with a dual expression system and bivalent peptide ligands

D. Lambert, G. Calo’, R. Guerrini, 2022, PloS one.

Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist

S. Salvadori, G. Balboni, D. Lambert, 2008, Peptides.

Desensitisation of native and recombinant human urotensin-II receptors

D. Lambert, G. Calo’, R. Guerrini, 2009, Naunyn-Schmiedeberg's Archives of Pharmacology.

Characterization and comparison of recombinant human and rat TRPV1 receptors: effects of exo- and endocannabinoids.

D. Lambert, J. McDonald, P. Lam, 2005, British journal of anaesthesia.

Nociceptin and urotensin-II concentrations in critically ill patients with sepsis.

S. P. Young, J. Williams, D. Lambert, 2008, British journal of anaesthesia.

Evidence for nociceptin/orphanin FQ (NOP) but not µ (MOP), δ (DOP) or κ (KOP) opioid receptor mRNA in whole human blood.

D. Lambert, J. McDonald, J. Thompson, 2016, British journal of anaesthesia.

In vitro and in vivo characterisation of the bifunctional MOP / DOP ligand UFP-505

Lambert, L., S. Salvadori, 2018 .

The Nociceptin/Orphanin FQ System Is Modulated in Patients Admitted to ICU with Sepsis and after Cardiopulmonary Bypass

D. Lambert, J. McDonald, N. Ladak, 2013, PloS one.

Evaluation of [Cys(ATTO 488)8]Dermorphin-NH2 as a novel tool for the study of μ-opioid peptide receptors

D. Lambert, G. Calo’, R. Guerrini, 2021, PloS one.

Long-term activation of polymorph cannabinoid receptors does not affect receptor gene transcription.

D. Lambert, L. Beishon, J. McDonald, 2014, British journal of anaesthesia.

S18 Activation of nociceptin orphanin FQ (N/OFQ) – N/OFQ peptide (NOP) receptor system plays a key immunomodulatory role in asthma

K. Urbanek, D. Lambert, G. Calo’, 2013, Thorax.

[Nphe1,Arg14,Lys15]Nociceptin‐NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor

S. Salvadori, D. Lambert, M. Morari, 2002, British journal of pharmacology.

Cannabinoid receptor expression in the bladder is altered in detrusor overactivity

D. Lambert, J. McDonald, D. Tincello, 2015, International Urogynecology Journal.

Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone‐inducible mammalian expression system

J. Williams, D. Lambert, G. Calo’, 2003, British journal of pharmacology.

Opioids, gliosis and central immunomodulation

D. Lambert, J. McDonald, S. Kadhim, 2018, Journal of Anesthesia.

[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a Highly Potent and Selective Agonist of the Nociceptin/Orphanin FQ Receptor

S. Salvadori, D. Lambert, M. Morari, 2005, Journal of Pharmacology and Experimental Therapeutics.

N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.

S. Salvadori, D. Lambert, G. Calo’, 2005, Journal of medicinal chemistry.

Binding of the novel radioligand [3H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors

D. Lambert, G. Calo’, R. Guerrini, 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist.

S. Salvadori, D. Lambert, G. Calo’, 2006, Bioorganic & medicinal chemistry.

Validation of endogenous control reference genes for normalizing gene expression studies in endometrial carcinoma.

D. Lambert, A. Taylor, E. Moss, 2015, Molecular human reproduction.

Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4)

M. Morari, C. Trapella, M. Volta, 2010, Peptides.

Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: In vitro and in vivo studies

S. Salvadori, G. Balboni, D. Lambert, 2006, Peptides.

Phosphorylation and activity of Na+/H+ exchanger isoform 1 of immortalized lymphoblasts in diabetic nephropathy.

B. Krolewski, A. Krolewski, J. McDonald, 1995, Diabetes.

Opioid Receptors

J. McDonald, D. Lambert, J. McDonald, 2015, Methods in Molecular Biology.

Anxiolytic and antidepressant-like activities of UFP-512, a novel selective delta opioid receptor agonist

S. Salvadori, G. Balboni, D. Lambert, 2006, European Neuropsychopharmacology.

Pharmacological characterization of the nociceptin / orphanin FQ receptor antagonist SB-612111: in vivo studies

D. Lambert, M. Morari, G. Calo’, 2007 .

Functional coupling of the nociceptin/orphanin FQ receptor in dog brain membranes

D. Lambert, R. Guerrini, J. McDonald, 2004, Brain Research.

Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma

C. Brightling, A. De Angelis, K. Urbanek, 2016, British journal of pharmacology.